Table 3.
Characteristics of patients by adjuvant therapy.
|
Parameters |
Targeted Therapy (n = 26) |
Cytokine Therapy (n = 74) |
P
Value |
| Sex, n | 1.000 | ||
| Male | 20 | 56 | |
| Female | 6 | 18 | |
| Age, mean (95% CI), y | 57.1 (52.5–61.8) | 59.8 (56.7–62.9) | |
| No. of levels | .015* | ||
| 1 | 15 | 57 | |
| 2 | 11 | 11 | |
| 3 | 0 | 3 | |
| Neurological status before surgery, n | <.0001* | ||
| Frankel A, B, C | 3 | 47 | |
| Frankel D, E | 23 | 27 | |
| Revised Tokuhashi score, mean (95% CI) | 11.1 (10.2–12.0) | 11.6 (11.1–12.1) | .328 |
| SINS, mean (95% CI) | 11.3 (9.6–13.1) | 10.9 (9.9–11.9) | .458 |
| Metastases, n | |||
| Synchronous | 11 | 55 | .007* |
| Solitary spinal metastases | 2 | 6 | 1.000 |
| Extravertebral bone metastases, n | 13 | 29 | .364 |
| Additional visceral metastases | 13 | 37 | 1.000 |
| Radical nephrectomy prior spine surgery, n | 24 | 63 | .505 |
| Metastasectomy, n | 7 | 32 | .167 |
Abbreviation: CI, confidence interval; SINS, Spinal Instability Neoplastic Score.
*
Statistically significant difference.